Evidence Trace, complete trial record

In plain terms

In plain terms: Chondroitin Sulfate shows early signals in human research but the evidence is limited -- small trials, surrogate endpoints, or not yet independently replicated. It is an emerging area, not yet a proven one.

Chondroitin Sulfate

C Limited: small, mixed or unreplicated trials

Category Supplements

Evidence Randomized trials and meta-analyses of randomized trials

Reviewed October 2026

PMIDs 28533290 · 30879253 · 16495392 · 17438317 · 20847017 · 25629804 · 30575881 · 38581640 · 27477804

The endpoint this grade is based on: self_report, Osteoarthritis pain and function; the large independent trials of chondroitin as generally sold were null or mixed, and the combination with glucosamine did no better than placebo

The evidence as the record states it

Evidence record

PMID 28533290 PMID 30879253 PMID 16495392 PMID 17438317 PMID 20847017 PMID 25629804 PMID 30575881 PMID 38581640 PMID 27477804

Reginster et al. (Annals of the Rheumatic Diseases, 2017; PMID 28533290), CONCEPT: 604 people with knee osteoarthritis, double-blind, pharmaceutical-grade chondroitin sulfate 800 mg a day, celecoxib or placebo for 182 days; chondroitin beat placebo on pain and the Lequesne index and matched celecoxib. Honvo et al. (Advances in Therapy, 2019; PMID 30879253): in low risk of bias trials, the pharmaceutical-grade preparation reduced pain and improved function and other preparations did not. The two papers come from the same research network and the preparation is one manufacturer's. That preparation is a registered medicine in several European countries and is not sold in the United States, so no letter on this page rests on it. For chondroitin as generally sold the large trials are null: Clegg et al. (New England Journal of Medicine, 2006; PMID 16495392), GAIT, 1,583 patients; Reichenbach et al. (Annals of Internal Medicine, 2007; PMID 17438317), effect near zero in the 3 large trials; Wandel et al. (BMJ, 2010; PMID 20847017), inside the minimal important difference; Singh et al. (Cochrane Database of Systematic Reviews, 2015; PMID 25629804), a small low-quality short-term benefit. Gregori et al. (JAMA, 2018; PMID 30575881) found no long-term pain benefit for chondroitin, only less joint space narrowing. Rabade et al. (Inflammopharmacology, 2024; PMID 38581640) found chondroitin alone helped and the combination with glucosamine did not; Roman-Blas et al. (Arthritis and Rheumatology, 2017; PMID 27477804) found the combination no better than placebo. Pain and function are self-reported. Chondroitin as sold to readers here is graded C.

PMID 28533290 PMID 30879253 PMID 16495392 PMID 17438317 PMID 20847017 PMID 25629804 PMID 30575881 PMID 38581640 PMID 27477804

Evidence by specific use

Osteoarthritis pain and function, chondroitin as generally sold

Grade C

The large, well-concealed trials are null: Clegg et al. (N Engl J Med, 2006; PMID 16495392), Reichenbach et al. (Ann Intern Med, 2007; PMID 17438317), Wandel et al. (BMJ, 2010; PMID 20847017). Singh et al. (Cochrane, 2015; PMID 25629804) found a small short-term benefit of low quality that became uncertain in the best trials, and Honvo et al. (Adv Ther, 2019; PMID 30879253) found non-pharmaceutical preparations did not reduce pain. Rabade et al. (Inflammopharmacology, 2024; PMID 38581640) was positive. Mixed: C.

PMID 16495392 PMID 17438317 PMID 20847017 PMID 25629804 PMID 30575881 PMID 38581640 PMID 30879253

Knee osteoarthritis pain and function, with glucosamine

Grade C

Roman-Blas et al. (Arthritis Rheumatol, 2017; PMID 27477804): the combination did worse than placebo on pain. Rabade et al. (Inflammopharmacology, 2024; PMID 38581640): the combination improved neither pain nor function across 3 trials. GAIT (Clegg et al., N Engl J Med, 2006; PMID 16495392) was not significant overall. C, close to D.

PMID 27477804 PMID 38581640 PMID 16495392

Why Grade C and not Grade B

Grade C reflects early or limited human evidence -- small trials, surrogate endpoints, or preliminary findings not yet independently replicated. The evidence points in a promising direction but does not yet meet the standard for Grade B. A single well-powered, independently replicated trial with a meaningful endpoint would move this to Grade B or higher.

What would move this grade

A well-powered randomized trial with an objective, clinically meaningful primary endpoint and at least one independent replication would support Grade B or higher.

How to track whether this is working Joint pain on the WOMAC or VAS scale at baseline, 8 weeks, and 16 weeks: the GAIT trial used WOMAC as the primary endpoint and showed benefit primarily in moderate-to-severe knee OA. Range of motion and stair-climbing time are practical functional secondary endpoints. Chondroitin requires 8-12 weeks before a meaningful response is detectable; do not judge efficacy at 4 weeks.